Cancer vaccines

Vaccination refers to the procedure pioneered by Edward Je (EJ), whereby the immune system is primed to respond rapid an infectious agent, by exposing it to the important antigens o infectious agent by using heat-killed or attenuated non-pathog versions. EJ used the biologically naturally attenuated humans), cow pox to provide resistance to small pox. A ca vaccine is designed to induce an immune response in a patien has developed cancer resistant to conventional treatment can who has a high probability of developing a recurrence follow adequate treatment. It is reasonable to regard cancer as an tion that has infected the host without inducing an approp immune response. The reasons that cancer cells are able to the immune system or an effective immune response include:

• Publication year

  2000

• Venue

  British Journal of Cancer

• Publication date

  2000-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1054/bjoc.2000.1217PMID 10817493PMCID 2374519
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BCG therapy in acute non lymphoid leukaemias.

  2009cited by this paper
• The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients

  2004cited by this paper
• Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines.

  2000cited by this paper
• Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection

  2000cited by this paper
• Prospects for Vaccination in Prostate Cancer

  2000cited by this paper
• 3-Fold increase in survival for stage IV melanoma patients treated with MCV allogeneic vaccine: confirmation of previous phase II data

  1999cited by this paper
• Role of dendritic cells in the induction and maintenance of autoimmune diseases

  1999cited by this paper
• CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

  1999cited by this paper
• Human tumor antigens for cancer vaccine development

  1999cited by this paper
• Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?

  1999cited by this paper
• Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.

  1999cited by this paper
• The relevance of non-linear mathematics (chaos theory) to the treatment of cancer, the role of the immune response and the potential for vaccines.

  1999cited by this paper
• BCG immunotherapy of bladder cancer: 20 years on.

  1999cited by this paper
• Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine

  1999cited by this paper
• Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.

  1999cited by this paper
• Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients

  1999cited by this paper
• Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma

  1999cited by this paper
• Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine

  1999cited by this paper
• How tumors escape immune destruction and what we can do about it

  1999cited by this paper
• Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes.

  1999cited by this paper
• The TRAIL to selective tumor death

  1999cited by this paper
• Development of dendritic cells and their use in tumor therapy.

  1999cited by this paper
• Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model

  1998cited by this paper
• Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172).

  1998cited by this paper
• Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.

  1998cited by this paper
• Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): Correlation with survival

  1998cited by this paper
• Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors.

  1998cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.

  1997cited by this paper
• Serological analysis of human tumor antigens: molecular definition and implications.

  1997cited by this paper
• Tumor antigens recognized by T cells.

  1997cited by this paper
• Aspirin and gastrointestinal cancer.

  1997cited by this paper
• Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.

  1996cited by this paper
• Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine.

  1996cited by this paper
• The case for therapeutic vaccines.

  1996cited by this paper
• Is cancer dangerous to the immune system?

  1996cited by this paper
• Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine

  1996cited by this paper
• Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.

  1995cited by this paper
• Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

  1994cited by this paper
• Heat shock protein-peptide complexes in cancer immunotherapy.

  1994cited by this paper
• Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.

  1993cited by this paper
• Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

  1992cited by this paper
• Coley toxins--the first century.

  1990cited by this paper
• Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action

  1990cited by this paper
• Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer.

  1982cited by this paper
• Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.

  1980cited by this paper
• Immunotherapy of Melanoma

  1979cited by this paper
• Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma

  1979cited by this paper
• Immunotherapy for Melanoma

  1973cited by this paper

• Effects of bamboo salt and its component, hydrogen sulfide, on enhancing immunity.

  2016cites this paper
• Active and passive immunization for cancer

  2014cites this paper
• Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment

  2008cites this paper
• Gamijeonssibaekchulsan regulates mast cell-mediated anaphylactic reaction.

  2007cites this paper
• The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model

  2006cites this paper
• The effect of Panax ginseng on forced immobility time & immune function in mice.

  2006cites this paper
• An herbal formula, Herbkines, enhances cytokines production from immune cells.

  2005cites this paper
• Cancer vaccines

  2005cites this paper
• Gamibojungikki-tang decreases immobility time on the forced swimming test and increases interferon-gamma production from MOLT-4 cells.

  2005cites this paper
• Therapeutic cancer vaccines: at midway between immunology and pharmacology.

  2005cites this paper
• The promise of cancer vaccines

  2004cites this paper
• The immune-enhancing effect of the herbal combination Bouum-Myunyuk-Dan.

  2004cites this paper
• Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model

  2004cites this paper
• Immune-enhancing effect of the Korean natural medicine WooKiEum.

  2004cites this paper
• Decrease of immobility behavior in forced-swimming test and immune system enhancing effect of traditional medicine Gamisipjundaebo-tang.

  2004cites this paper
• Immune-enhancement effect of the herbal combination Allergina.

  2003cites this paper
• Critical appraisals of approaches for predictive designs in anticancer drugs

  2002cites this paper
• Therapeutic cancer vaccines on trial

  2002cites this paper
• Spontaneous regression: a hidden treasure buried in time.

  2002cites this paper
• Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy

  2002cites this paper
• Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity1

  2002cites this paper
• Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes.

  2001cites this paper
• Cancer gene therapy: developments to 2000

  2000cites this paper